Skip to content
ESPT
MARKETS / NYSE / Health care / Health services / DVA
NYSE · SERVICES-MISC HEALTH & ALLIED SERVICES, NEC · LARGE CAP

DaVita Inc. DVA

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$13.6B
▲ 6.5% YoY
$746.8M
▼ 20.2% YoY
$1.3B
▼ 10.6% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

DaVita provides dialysis, administrative, and related laboratory services to patients with chronic kidney failure in the United States. As of December 31, 2025, the company provided dialysis, administrative and related laboratory services to approximately 200,500 patients. As of December 31, 2025, the company employed approximately 78,000 teammates, with approximately 72% of them located within the United States. The company also maintains other ancillary services and investments outside of its U.S. dialysis, U.S. integrated kidney care, and international operations. As of December 31, 2025, the company's international operations provided dialysis and administrative services to 585 outpatient dialysis centers located in 14 countries outside the United States, serving approximately 94,500 patients. The company's U.S. integrated kidney care business provided integrated care and disease management services to 66,000 patients in risk-based integrated care arrangements and to an additional 9,400 patients in other integrated care arrangements across the United States as of December 31, 2025.

Written from the business description in DAVITA INC.'s annual report to the U.S. Securities and Exchange Commission, filed 11 February 2026. Every sentence was checked against that document before publication.

Growth

USD 13.6B
Revenue, FY2025 · full 19-year series below
Revenue $B Net income $B
FY2025 · Revenue 13.6 · Net income 0.7
5B10B
2007201020132016201920222025
Compound annual growth
+5.5%
+3.4%
+3.2%
+5.4%
+10.0%
−0.7%
+10.7%
+4.2%
+18.9%
+9.3%
+22.9%
+17.7%
−2.1%
+9.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +3.4% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

8 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 15.0% · Net 7.9%
5%10%15%
200720162025
ROE
FY2024 · ROE 159.1%
50%100%150%
200720162025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Gross margin·
Operating margin15.0%
Net margin7.9%
EBITDAUSD 2.8B

Return on equity has no reading this year — return on capital employed, just below, still does: 14%.

Cash & shareholders

USD 1.3B
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF 1.3
1B2B
200720162025
Net buybacks $B Dividends $B
FY2025 · Dividends 0.0 · Net buybacks 1.3
1B2B
200720092011201620182020202220242025
Dividends paidUSD 0.00
Net buybacksUSD 1.3B
Share of profit175.2%
Consecutive raises·

USD 1.3B in buybacks — 175% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 17.5B
EquityUSD -651.1M
CashUSD 676.4M
Gross debtUSD 10.2B
Net debtUSD 9.5B
Current ratio1.29×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
DVA, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B13.612.812.111.611.611.611.411.410.910.710.012.811.88.26.76.2◌◌◌
Operating income $B2.02.11.61.31.81.71.61.51.82.01.11.81.61.31.21.00.90.90.9
EBITDA $B2.82.82.32.12.52.32.22.12.42.51.62.21.91.61.41.21.21.1◌
Income tax $B0.30.30.20.20.30.30.30.30.30.40.20.40.40.40.30.30.30.20.2
Net income $B0.70.90.70.61.00.80.80.20.70.90.30.70.60.50.50.40.40.40.4
Free cash flow $B1.31.51.51.01.31.31.30.81.01.10.80.81.20.60.80.60.40.30.3
EPS, diluted $9.8410.737.425.858.906.315.270.923.474.291.253.332.952.742.483.944.063.533.55
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout %00000000———————————
ROE %—159.178.276.491.544.027.83.814.218.55.415.115.518.223.219.721.721.2◌
Shares out B0.070.080.090.090.100.110.130.170.180.190.210.220.210.110.090.100.100.10◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

DaVita Inc.vsHCA Healthcare, Inc.Same industry: Services-Misc Health & Allied Services, NECDaVita Inc.vsTenet Healthcare Corp.Same industry: Services-Misc Health & Allied Services, NECDaVita Inc.vsUniversal Health Services Inc.Same industry: Services-Misc Health & Allied Services, NECDaVita Inc.vsFresenius Medical Care AGSame industry: Services-Misc Health & Allied Services, NECDaVita Inc.vsLabcorp Holdings Inc.Same industry: Services-Misc Health & Allied Services, NECDaVita Inc.vsBrightSpring Health Services, Inc.Same industry: Services-Misc Health & Allied Services, NECDaVita Inc.vsQuest Diagnostics Inc.Same industry: Services-Misc Health & Allied Services, NEC
More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 74 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Two checks were skipped: the balance sheet is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityServices-Misc Health & Allied Services, NEC
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2007

Share this section

Download image